AR082566A1 - Formulaciones liquidas de st-246 y metodos relacionados, proceso - Google Patents
Formulaciones liquidas de st-246 y metodos relacionados, procesoInfo
- Publication number
- AR082566A1 AR082566A1 ARP110102829A ARP110102829A AR082566A1 AR 082566 A1 AR082566 A1 AR 082566A1 AR P110102829 A ARP110102829 A AR P110102829A AR P110102829 A ARP110102829 A AR P110102829A AR 082566 A1 AR082566 A1 AR 082566A1
- Authority
- AR
- Argentina
- Prior art keywords
- polymorph form
- cyclodextrin
- related methods
- liquid formulations
- liquid
- Prior art date
Links
- CSKDFZIMJXRJGH-VWLPUNTISA-N tecovirimat Chemical compound C1=CC(C(F)(F)F)=CC=C1C(=O)NN1C(=O)[C@@H]([C@@H]2[C@H]3C[C@H]3[C@H]3C=C2)[C@@H]3C1=O CSKDFZIMJXRJGH-VWLPUNTISA-N 0.000 title abstract 10
- 238000000034 method Methods 0.000 title abstract 4
- 239000012669 liquid formulation Substances 0.000 title abstract 2
- 229920000858 Cyclodextrin Polymers 0.000 abstract 3
- 239000007788 liquid Substances 0.000 abstract 3
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 239000004615 ingredient Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- ODLHGICHYURWBS-FOSILIAISA-N molport-023-220-444 Chemical compound CC(O)COC[C@@H]([C@@H]([C@H]([C@@H]1O)O)O[C@@H]2O[C@H]([C@H](O[C@@H]3O[C@@H](COCC(C)O)[C@@H]([C@H]([C@@H]3O)O)O[C@@H]3O[C@@H](COCC(C)O)[C@@H]([C@H]([C@@H]3O)O)O[C@@H]3O[C@@H](COCC(C)O)[C@@H]([C@H]([C@@H]3O)O)O[C@@H]3O[C@@H](COCC(C)O)[C@@H]([C@H]([C@@H]3O)O)O3)[C@@H](O)[C@@H]2O)COCC(O)C)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O)[C@H]3O[C@H]1COCC(C)O ODLHGICHYURWBS-FOSILIAISA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/02—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms
- A01N43/04—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms with one hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24071—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Dentistry (AREA)
- Biotechnology (AREA)
- Pest Control & Pesticides (AREA)
- Agronomy & Crop Science (AREA)
- Environmental Sciences (AREA)
- Plant Pathology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Cosmetics (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37097110P | 2010-08-05 | 2010-08-05 | |
| US201161450359P | 2011-03-08 | 2011-03-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR082566A1 true AR082566A1 (es) | 2012-12-19 |
Family
ID=45559790
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110102829A AR082566A1 (es) | 2010-08-05 | 2011-08-04 | Formulaciones liquidas de st-246 y metodos relacionados, proceso |
Country Status (15)
| Country | Link |
|---|---|
| US (5) | US9233097B2 (enExample) |
| EP (1) | EP2600715B1 (enExample) |
| JP (1) | JP5898196B2 (enExample) |
| KR (1) | KR101868117B1 (enExample) |
| CN (2) | CN103281898A (enExample) |
| AR (1) | AR082566A1 (enExample) |
| AU (1) | AU2011285871B8 (enExample) |
| BR (1) | BR112013002646B1 (enExample) |
| CA (1) | CA2807528C (enExample) |
| DK (1) | DK2600715T3 (enExample) |
| IL (1) | IL224430B (enExample) |
| MX (2) | MX347795B (enExample) |
| SG (3) | SG10202105262QA (enExample) |
| WO (1) | WO2012018810A1 (enExample) |
| ZA (1) | ZA201300930B (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8530509B2 (en) | 2003-06-20 | 2013-09-10 | Siga Technologies, Inc. | Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases |
| CN104414983B (zh) * | 2013-08-28 | 2018-09-04 | 山东新时代药业有限公司 | 一种注射用福沙匹坦二甲葡胺无菌冻干粉末及其制备工艺 |
| US10406103B2 (en) | 2013-11-19 | 2019-09-10 | Siga Technologies Inc. | Rehydration of micronized tecovirmimat monohydrate |
| EP3154535A4 (en) * | 2014-06-12 | 2018-02-14 | University of Notre Dame du Lac | Composition and method for the treatment of neurological diseases and cerebral injury |
| CN105816422B (zh) * | 2015-01-05 | 2020-08-14 | 天士力医药集团股份有限公司 | 一种水飞蓟宾注射剂及其制备方法 |
| US10488733B2 (en) | 2015-04-10 | 2019-11-26 | Bae Systems Plc | Long range electromagnetic radiation sensor having a control system to heat and/or ionize the air within three-dimensional portions of an atmospheric volume |
| CN107625967B (zh) | 2016-07-15 | 2021-07-06 | 中国人民解放军军事医学科学院毒物药物研究所 | 一种特考韦瑞注射用药物组合物及其制备方法 |
| CN107638571B (zh) * | 2016-07-15 | 2021-07-06 | 中国人民解放军军事医学科学院毒物药物研究所 | 一种特考韦瑞口服药物组合物及其制备方法 |
| CN106407676A (zh) * | 2016-09-12 | 2017-02-15 | 广东省农业科学院动物科学研究所 | 一种基于蒙特卡罗模拟的抗菌药物药效计算方法 |
| US10478422B1 (en) | 2018-12-14 | 2019-11-19 | ECI Pharmaceuticals, LLC | Oral liquid compositions including valsartan |
| US11413275B1 (en) | 2018-12-14 | 2022-08-16 | ECI Pharmaceuticals, LLC | Oral liquid compositions including valsartan |
| US11446243B1 (en) * | 2019-08-05 | 2022-09-20 | ECI Pharmaceuticals, LLC | Oral liquid compositions including valsartan |
| US12226431B2 (en) * | 2021-09-11 | 2025-02-18 | Porosome Therapeutics, Inc. | Aerosol and topical administration of a formulation containing cyclodextrin, quercetin and zinc, in combination or separately, to mitigate infection by enveloped viruses |
| CN116211821A (zh) * | 2023-02-06 | 2023-06-06 | 青岛增益安生物科技有限公司 | 一种特考韦瑞的药物混合方式 |
| US11903962B1 (en) | 2023-05-07 | 2024-02-20 | Michael Farber | Isoxazoline complexes and compositions thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003215027A1 (en) | 2002-03-21 | 2003-10-08 | Regents Of The University Of Minnesota | Cyclodextrin compositions and methods of treating viral infections |
| WO2004112718A2 (en) * | 2003-06-20 | 2004-12-29 | Siga Technologies, Inc. | Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases |
| EP1831210A1 (en) * | 2004-12-23 | 2007-09-12 | Pfizer Limited | 8-aza-bicyclo[3.2.1]octane derivatives with an activity on chemokine ccr5 receptors |
| JP2008535862A (ja) * | 2005-04-08 | 2008-09-04 | キメリクス，インコーポレイテッド | ポックスウイルス感染の治療のための化合物、組成物および方法 |
| SI2335707T1 (sl) * | 2005-10-26 | 2015-09-30 | Cydex Pharmaceuticals, Inc. | Sestavki sulfoalkil eter ciklodekstrina in metode za njihovo pripravo |
| BRPI0719096A2 (pt) * | 2006-11-21 | 2013-12-03 | Novartis Ag | Formulação parenteral estavel contendo uminibidor de rsv de uma estrutura de benzodiazepina |
| CA2685153C (en) * | 2007-04-23 | 2014-12-16 | Siga Technologies, Inc. | Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases |
| EP2313111B1 (en) | 2008-08-01 | 2013-09-04 | Ventirx Pharmaceuticals, Inc. | Toll-like receptor agonist formulations and their use |
-
2011
- 2011-08-02 SG SG10202105262QA patent/SG10202105262QA/en unknown
- 2011-08-02 BR BR112013002646-4A patent/BR112013002646B1/pt active IP Right Grant
- 2011-08-02 SG SG10201506031UA patent/SG10201506031UA/en unknown
- 2011-08-02 CN CN2011800480431A patent/CN103281898A/zh active Pending
- 2011-08-02 KR KR1020137005710A patent/KR101868117B1/ko active Active
- 2011-08-02 MX MX2013001389A patent/MX347795B/es active IP Right Grant
- 2011-08-02 DK DK11815188.5T patent/DK2600715T3/da active
- 2011-08-02 MX MX2017006160A patent/MX368106B/es unknown
- 2011-08-02 SG SG2013007000A patent/SG187243A1/en unknown
- 2011-08-02 AU AU2011285871A patent/AU2011285871B8/en active Active
- 2011-08-02 JP JP2013523271A patent/JP5898196B2/ja active Active
- 2011-08-02 EP EP11815188.5A patent/EP2600715B1/en active Active
- 2011-08-02 WO PCT/US2011/046260 patent/WO2012018810A1/en not_active Ceased
- 2011-08-02 CN CN201610599807.0A patent/CN106074370A/zh active Pending
- 2011-08-02 US US13/814,102 patent/US9233097B2/en active Active
- 2011-08-02 CA CA2807528A patent/CA2807528C/en active Active
- 2011-08-04 AR ARP110102829A patent/AR082566A1/es not_active Application Discontinuation
-
2013
- 2013-01-27 IL IL224430A patent/IL224430B/en active IP Right Grant
- 2013-02-04 ZA ZA2013/00930A patent/ZA201300930B/en unknown
-
2015
- 2015-12-01 US US14/955,674 patent/US9907859B2/en active Active
-
2018
- 2018-01-16 US US15/872,505 patent/US10124071B2/en active Active
- 2018-10-11 US US16/157,343 patent/US10576165B2/en active Active
-
2020
- 2020-01-02 US US16/732,509 patent/US10864282B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR082566A1 (es) | Formulaciones liquidas de st-246 y metodos relacionados, proceso | |
| PE20130230A1 (es) | Derivados de carboxamidas n-azabiciclicas y su preparacion | |
| MX375001B (es) | Formulacion de premezcla de dexmedetomidina. | |
| CL2012000261A1 (es) | Composición farmacéutica líquida de ácido 4- {[9-cloro-7-(2-fluoro-6-metoxifenil)-5h-pirimido[5,4-d][2]benzazepin-2-il]amino}-2-metoxibenzoico en una mezcla de disolventes con al menos 15% de propilenglicol, 15% de peg400 y menos de 50% de agua; y su uso para la preparación de un medicamento para el tratamiento de cáncer. | |
| EA201391758A1 (ru) | Спрессованная сердцевина для фармацевтической композиции, содержащая органические кислоты | |
| FR2986002A1 (fr) | Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
| EA201001555A1 (ru) | Антиоксидативные модуляторы воспаления: производные олеанолевой кислоты с аминовыми и другими модификациями на с-17 | |
| AR086823A1 (es) | Formulaciones de anticuerpo anti-c-met, metodos | |
| AR102926A1 (es) | Composiciones anticancerosas | |
| MX2014015005A (es) | Formas cristalinas de un modulador del receptor androgenico. | |
| EA201391313A1 (ru) | C4-монометилтритерпеноидные производные и способы их применения | |
| CL2013000063A1 (es) | Un método para tratar a un sujeto que comprende administrar n-etil-n-fenil1,2-dihidroxi-4-hodroxi-5-cloro-1-metil-2-oxoquinolina-3-carboxamida opcionalmente deuterada, para el tratamiento de una enfermedad autoinmunitaria; una mezcla de los mismos; composición farmaceutica y su proceso de preparacion. | |
| WO2014101986A8 (en) | Dry granulation process for producing tablet compositions of metformin and compositions thereof | |
| CR20140037A (es) | Antagonistas trpm8 y su uso en tratamientos | |
| ECSP14013231A (es) | Imidazopiridazinas sustituidas con amino | |
| AR089990A1 (es) | Dispositivo con nucleo y recubrimiento para la liberacion de farmacos | |
| CL2010001348A1 (es) | Compuestos derivados de 1-oxo-2,3-dihidro-1h-isoindolin-5-il)-isoxazol-3-carboxamida, potenciadores de los mglur2; composicion farmaceutica; y su uso para aliviar los sintomas o disminuir la aparicion de los sintomas de ezquizofrenia o ansiedad. | |
| EA201500650A1 (ru) | Фенилацетат l-орнитина и способы его получения | |
| BR112015000229A2 (pt) | formulações aquosas estáveis de etanercept | |
| CL2016000510A1 (es) | Composiciones para comprimidos bucodispersables que contienen corticosteroides para esofagitis eosinofílica | |
| EA201490395A1 (ru) | Способ получения фармацевтических композиций, содержащих финголимод | |
| CL2011001860A1 (es) | Compuestos derivados de indol; procedimiento de preparacion de dichos compuestos; composicion y combinacion farmaceutica; y uso en el tratamiento del cancer. | |
| EA201200616A1 (ru) | Производные 2-оксо-1-пирролидинилимидазотиадиазола | |
| EA201291014A1 (ru) | Трициклическое индазольное соединение, способ его получения и содержащая его фармацевтическая композиция | |
| EA201490363A1 (ru) | Новые составы на основе (триметоксифениламино)пиримидинилов |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |